ifferent Phenotypes in Asthma: Clinical Findings and Experimental Animal Model

Author(s)

Lourenco, Luiz Otavio ^[1] ; Ribeiro, Alessandra Mussi ^[1] ; Quirino Dos Santos Lopes, Fernanda Degobbi Tenorio ^[2] ; Lopes Calvo Tiberio, Iolanda de Fatima ^[2] ; Tavares-de-Lima, Wothan ^[3] ; Prado, Carla Maximo ^{[2, 1]}

Affiliation

^[1] Univ Fed Sao Paulo, Dept Biosci, Campus Baixada Santista, Santos, SP - Brazil

^[2] Univ Sao Paulo, Sch Med, Dept Med, Sao Paulo, SP - Brazil

^[3] Univ Sao Paulo, Inst Biomed Sci, Dept Pharmacol, Sao Paulo, SP - Brazil

• Document type: Journal article
• Source: CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY; v. 62, n. 1, SI SEP 2021.
• Web of Science Citations: 0

Abstract

Asthma is a respiratory allergic disease presenting a high prevalence worldwide, and it is responsible for several complications throughout life, including death. Fortunately, asthma is no longer recognized as a unique manifestation but as a very heterogenic manifestation. Its phenotypes and endotypes are known, respectively, as pathologic and molecular features that might not be directly associated with each other. The increasing number of studies covering this issue has brought significant insights and knowledge that are constantly expanding. In this review, we intended to summarize this new information obtained from clinical studies, which not only allowed for the creation of patient clusters by means of personalized medicine and a deeper molecular evaluation, but also created a connection with data obtained from experimental models, especially murine models. We gathered information regarding sensitization and trigger and emphasizing the most relevant phenotypes and endotypes, such as Th2-(high) asthma and Th2-(low) asthma, which included smoking and obesity-related asthma and mixed and paucigranulocytic asthma, not only in physiopathology and the clinic but also in how these phenotypes can be determined with relative similarity using murine models. We also further investigated how clinical studies have been treating patients using newly developed drugs focusing on specific biomarkers that are more relevant according to the patient's clinical manifestation of the disease. (AU)

• FAPESP's process: 18/06088-0 - Effects of eugenol and dehidrodieugenol isolated from Nectandra leucantha (Lauraceae) treatments in experimental models of acute and chronic lung disease
• Grantee: Carla Máximo Prado
• Support Opportunities: Regular Research Grants